HIV Infections Clinical Trial
Official title:
Brief Introductory Therapy for Opioid Dependence
A randomized clinical trial to compare the efficacy of Behavioral Drug and HIV Risk Reduction Counseling (BDRC) and standard methadone drug counseling.
The proposed study plans to compare the efficacy of behavioral drug and HIV risk reduction
counseling (BDRC) to low intensity methadone counseling during methadone maintenance
treatment. In selecting BDRC, we were guided by several considerations, including its
acceptability, suitability, feasibility, potential efficacy, and potential for rapid and
widespread dissemination in the U.S. and elsewhere. BDRC was developed to be delivered by
regular drug counselors, so that it would be relatively easy to disseminate this counseling
if it is found efficacious. BDRC combines behavioral contracting with an
Information-Motivation-Behavioral Skills (IMB) model for reducing HIV risk behaviors and
illicit drug use that is grounded in social cognitive theory and supported by empirical
findings in a number of studies and populations. The more intensive HIV risk reduction
interventions provided in BDRC, including personalized assessment of risk (i.e.,
identification of personal, social and environmental factors associated with risky behaviors)
and education and training in skill-building and self-control, may lead to greater reductions
in both drug- and sex-related HIV risk behaviors than the more limited, brief counseling
provided in LIMC, as supported by findings of a recent clinical trial with methadone
maintained patients and a meta-analysis regarding the effectiveness of HIV risk reduction
interventions during drug abuse treatment. BDRC emphasizes a medical model of treatment for
drug dependence and is highly complementary to and compatible with regular methadone
maintenance treatment.
Because early abstinence achievement is associated with longer term treatment success, BDRC
uses short-term behavioral contracts to help the patient achieve an initial period of
abstinence, take maintenance medications regularly and as prescribed, activate the patient
behaviorally, and reduce behaviors associated with HIV transmission. The accomplishment of
specific, short-term behavioral goals early in treatment promotes the patient's experience of
therapeutic success and counters the patient's belief that his/her actions will not lead to
success in accomplishing goals. Short-term behavioral goals target a limited number of
domains, including achieving an initial period of abstinence, increasing activities
(primarily vocational, social or recreational) that are not related to drug use, and reducing
HIV risk behaviors (e.g., fostering consistent condom use, avoiding casual sexual encounters,
avoiding IDU or needle or equipment sharing). BDRC teaches cognitive and behavioral
strategies for promoting behavioral change, including identifying antecedents of drug use,
needle sharing, and high risk sexual behaviors, and learning strategies to avoid high risk
situations or cope without engaging in these behaviors. Skill building exercises (e.g.,
regarding condom use) are used within sessions to learn and practice new skills, and patients
are encouraged to practice these skills outside the session in their natural environment.
Based on recent findings from research in cognitive and social psychology on message framing,
the treatment also emphasizes the positive consequences of behavioral change (e.g., the
benefits of not using drugs or of maintaining a steady relationship vs. the dangers
associated with continued use or sex with multiple partners). Counselors are trained to
acknowledge the patient's efforts to change—even partial accomplishments of goals are
praised--rather than to focus on the patient's failures, which is often perceived as
criticism. Recognition of accomplishments and positively framed messages generally evoke
positive affect, which is often generalized and ascribed to the behavior in question, thus
resulting in greater adherence to recommendations. An emphasis on recognition of
accomplishments and positively-framed advice helps patients to build self-esteem and the
sense that they can change their lives for the better.
Substance abuse is thought to be associated with a range of memory and executive function
(EFs) deficits, but the majority of research support for this hypothesis comes from research
on alcohol and stimulant related disorders. The evidence of long-term cognitive deficits in
chronic opiate users is limited, nonetheless most consistently it suggests that EFs may be
affected by chronic opiate use. Because BDRC incorporates many cognitive behavioral
therapeutic techniques, includes educational and learning components and aims at improving
decision making skills of the patients, we plan to evaluate a broad range of memory and
executive functions of patients enrolled in the proposed study in order to identify common
EFs impairments, evaluate if such impairments interfere with treatment efficacy, and if
additional treatment components are necessary and can be devised in order to improve
treatment efficacy for patients with cognitive impairments. We also plan to evaluate if
cognitive performance improves during methadone maintenance treatment when combined with BDRC
and evaluate whether presence or absence of impairments are associated with differential
effects of treatments.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |